Cargando…

Prognostic value of ERBB4 expression in patients with triple negative breast cancer

BACKGROUND: Triple-negative breast cancer (TNBC) is known for aggressive biologic features and poor prognosis. Epidermal growth factor receptor (EGFR) overexpression in TNBC indicates poor prognosis. However, there is no previous study of the relationship between expression of the entire human epide...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Ji-Yeon, Jung, Hae Hyun, Do, In-Gu, Bae, SooYoun, Lee, Se Kyung, Kim, Seok Won, Lee, Jeong Eon, Nam, Seok Jin, Ahn, Jin Seok, Park, Yeon Hee, Im, Young-Hyuck
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763414/
https://www.ncbi.nlm.nih.gov/pubmed/26907936
http://dx.doi.org/10.1186/s12885-016-2195-3
_version_ 1782417255676510208
author Kim, Ji-Yeon
Jung, Hae Hyun
Do, In-Gu
Bae, SooYoun
Lee, Se Kyung
Kim, Seok Won
Lee, Jeong Eon
Nam, Seok Jin
Ahn, Jin Seok
Park, Yeon Hee
Im, Young-Hyuck
author_facet Kim, Ji-Yeon
Jung, Hae Hyun
Do, In-Gu
Bae, SooYoun
Lee, Se Kyung
Kim, Seok Won
Lee, Jeong Eon
Nam, Seok Jin
Ahn, Jin Seok
Park, Yeon Hee
Im, Young-Hyuck
author_sort Kim, Ji-Yeon
collection PubMed
description BACKGROUND: Triple-negative breast cancer (TNBC) is known for aggressive biologic features and poor prognosis. Epidermal growth factor receptor (EGFR) overexpression in TNBC indicates poor prognosis. However, there is no previous study of the relationship between expression of the entire human epidermal growth factor receptor (HER) family genes and patient prognosis in TNBC. Accordingly, we investigated the expression profiles of HER family genes in patients with TNBC to determine the prognostic value and clinical implications of HER family expression. METHODS: We used the nCounter expression assay (NanoString®) to measure the expression of EGFR, erb-B2 receptor tyrosine kinase 2 (ERBB2), ERBB3, ERBB4, and estrogen receptor 1 (ESR1) genes using mRNA extracted from paraffin-embedded tumor tissues from 203 patients diagnosed with TNBC. Our data were validated using a separate cohort of 84 TNBC patients. RESULTS: A total of 203 TNBC patients who received adjuvant chemotherapy after curative surgery from 2000 to 2004 formed the training set. The 84 TNBC patients in the validation consort were selected from breast cancer patients who received curative surgery since 2005 to 2010. Analysis of the expression profiles of the HER family genes in TNBC tissue specimens revealed that increased expression of ERBB4 was associated with poor prognosis according to survival analysis (5-year distant relapse free survival [5Y DRFS], low vs. high expression [cut-off: median]: 90.1 % vs. 80.2 %; p = 0.022). This trend was also observed in the validation set of TNBC patients (5Y DRFS, low vs. high: 69.4 % vs. 44.7 %; p = 0.053). In a multivariate Cox regression model, ERBB4 expression was identified as a indicator of long-term prognosis in patients with TNBC. CONCLUSIONS: The expression profile of ERBB4, a member of the HER family, might serve as a prognostic marker in patients with TNBC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2195-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4763414
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47634142016-02-24 Prognostic value of ERBB4 expression in patients with triple negative breast cancer Kim, Ji-Yeon Jung, Hae Hyun Do, In-Gu Bae, SooYoun Lee, Se Kyung Kim, Seok Won Lee, Jeong Eon Nam, Seok Jin Ahn, Jin Seok Park, Yeon Hee Im, Young-Hyuck BMC Cancer Research Article BACKGROUND: Triple-negative breast cancer (TNBC) is known for aggressive biologic features and poor prognosis. Epidermal growth factor receptor (EGFR) overexpression in TNBC indicates poor prognosis. However, there is no previous study of the relationship between expression of the entire human epidermal growth factor receptor (HER) family genes and patient prognosis in TNBC. Accordingly, we investigated the expression profiles of HER family genes in patients with TNBC to determine the prognostic value and clinical implications of HER family expression. METHODS: We used the nCounter expression assay (NanoString®) to measure the expression of EGFR, erb-B2 receptor tyrosine kinase 2 (ERBB2), ERBB3, ERBB4, and estrogen receptor 1 (ESR1) genes using mRNA extracted from paraffin-embedded tumor tissues from 203 patients diagnosed with TNBC. Our data were validated using a separate cohort of 84 TNBC patients. RESULTS: A total of 203 TNBC patients who received adjuvant chemotherapy after curative surgery from 2000 to 2004 formed the training set. The 84 TNBC patients in the validation consort were selected from breast cancer patients who received curative surgery since 2005 to 2010. Analysis of the expression profiles of the HER family genes in TNBC tissue specimens revealed that increased expression of ERBB4 was associated with poor prognosis according to survival analysis (5-year distant relapse free survival [5Y DRFS], low vs. high expression [cut-off: median]: 90.1 % vs. 80.2 %; p = 0.022). This trend was also observed in the validation set of TNBC patients (5Y DRFS, low vs. high: 69.4 % vs. 44.7 %; p = 0.053). In a multivariate Cox regression model, ERBB4 expression was identified as a indicator of long-term prognosis in patients with TNBC. CONCLUSIONS: The expression profile of ERBB4, a member of the HER family, might serve as a prognostic marker in patients with TNBC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2195-3) contains supplementary material, which is available to authorized users. BioMed Central 2016-02-22 /pmc/articles/PMC4763414/ /pubmed/26907936 http://dx.doi.org/10.1186/s12885-016-2195-3 Text en © Kim et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Kim, Ji-Yeon
Jung, Hae Hyun
Do, In-Gu
Bae, SooYoun
Lee, Se Kyung
Kim, Seok Won
Lee, Jeong Eon
Nam, Seok Jin
Ahn, Jin Seok
Park, Yeon Hee
Im, Young-Hyuck
Prognostic value of ERBB4 expression in patients with triple negative breast cancer
title Prognostic value of ERBB4 expression in patients with triple negative breast cancer
title_full Prognostic value of ERBB4 expression in patients with triple negative breast cancer
title_fullStr Prognostic value of ERBB4 expression in patients with triple negative breast cancer
title_full_unstemmed Prognostic value of ERBB4 expression in patients with triple negative breast cancer
title_short Prognostic value of ERBB4 expression in patients with triple negative breast cancer
title_sort prognostic value of erbb4 expression in patients with triple negative breast cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4763414/
https://www.ncbi.nlm.nih.gov/pubmed/26907936
http://dx.doi.org/10.1186/s12885-016-2195-3
work_keys_str_mv AT kimjiyeon prognosticvalueoferbb4expressioninpatientswithtriplenegativebreastcancer
AT junghaehyun prognosticvalueoferbb4expressioninpatientswithtriplenegativebreastcancer
AT doingu prognosticvalueoferbb4expressioninpatientswithtriplenegativebreastcancer
AT baesooyoun prognosticvalueoferbb4expressioninpatientswithtriplenegativebreastcancer
AT leesekyung prognosticvalueoferbb4expressioninpatientswithtriplenegativebreastcancer
AT kimseokwon prognosticvalueoferbb4expressioninpatientswithtriplenegativebreastcancer
AT leejeongeon prognosticvalueoferbb4expressioninpatientswithtriplenegativebreastcancer
AT namseokjin prognosticvalueoferbb4expressioninpatientswithtriplenegativebreastcancer
AT ahnjinseok prognosticvalueoferbb4expressioninpatientswithtriplenegativebreastcancer
AT parkyeonhee prognosticvalueoferbb4expressioninpatientswithtriplenegativebreastcancer
AT imyounghyuck prognosticvalueoferbb4expressioninpatientswithtriplenegativebreastcancer